{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:24:22Z","timestamp":1780471462517,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) with fetal liver tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) is associated with poor prognosis, and allogeneic stem cell transplantation (Allo-SCT) seems to be the preferred therapeutic approach. However, the predictors of post-transplant outcomes were not well-defined. The aim of the study was to evaluate the significance of <jats:italic>FLT3\/ITD<\/jats:italic> mutation by polymerase chain reaction as minimal residual disease (MRD) marker of outcomes after transplantation. We identified 43 patients (28\u00a0females and 15 males) with FLT3-mutated AML at the median age of 45\u00a0years who were allografted between 2009 and 2019. Hematological status at transplant was as follows: the first complete remission (CR1) in 29 patients, CR2 in 5, and 9 patients were transplanted in marrow aplasia (MA). Twenty-seven patients were FLT3 MRD negative at transplant. Median time from diagnosis to transplant was 16.7\u00a0months. Post-allograft CR rate was 88%. The relapse incidence (RI) was lower for patients who were FLT3 MRD negative at transplant when compared with those with FLT3\u00a0MRD positivity (41% vs 59%; <jats:italic>p<\/jats:italic>\u2009=\u20090.01). The patients who eradicated <jats:italic>FLT3\/ITD<\/jats:italic> at day +\u200930 after transplant had lower RI than those with detectable <jats:italic>FLT3\/ITD<\/jats:italic> (23% vs 76%; <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;0.001). The 2-year LFS and OS were 53% and 54%, with the median OS and LFS of 28\u00a0months and 27\u00a0months, respectively. Patients with CR1\/2 and FLT3 MRD(\u2212) had a 2-year OS of 80%. The FLT3 MRD negativity at transplant prolonged LFS in multivariate analysis (HR 5.3 95%CI 1.97\u201314.2); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), whereas FLT3 MRD negativity and unrelated donor predicted favorable OS.<\/jats:p>","DOI":"10.1007\/s00277-020-04026-1","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T12:22:38Z","timestamp":1587730958000},"page":"1845-1853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pre-transplant FLT3\/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-1268","authenticated-orcid":false,"given":"Grzegorz","family":"Helbig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wo\u017aniczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kopi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Boral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Grygoruk-Wi\u015bniowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Stachowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Karolczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"4026_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc1169","volume":"3","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Radich JP (2003) The role of FLT3 in hematopoietic malignancies. Nat Rev Cancer 3:650\u2013665","journal-title":"Nat Rev Cancer"},{"key":"4026_CR2","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","volume":"100","author":"S Fr\u04e7hling","year":"2002","unstructured":"Fr\u04e7hling S, Schlenk RF, Breitruck J et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm. Blood. 100:4372\u20134380","journal-title":"Blood."},{"key":"4026_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/sj.leu.2401731","volume":"14","author":"WJ Rombouts","year":"2000","unstructured":"Rombouts WJ, Blokland I, Lowenberg B et al (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 14:675\u2013683","journal-title":"Leukemia."},{"key":"4026_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u04e7hner","year":"2017","unstructured":"D\u04e7hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424\u2013447","journal-title":"Blood."},{"key":"4026_CR5","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1182\/blood-2006-09-047225","volume":"109","author":"M Bornhauser","year":"2007","unstructured":"Bornhauser M, Illmer T, Schaich M et al (2007) Improved outcome after stem-cell transplantation in FLT3-ITD positive AML. Blood. 109:2264\u20132265","journal-title":"Blood."},{"key":"4026_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.leukres.2012.10.005","volume":"37","author":"PH Lin","year":"2013","unstructured":"Lin PH, Lin CC, Yang HI, Li LY, Bai LY, Chiu CF, Liao YM, Lin CY, Hsieh CY, Lin CY, Ho CM, Yang SF, Peng CT, Tsai FJ, Yeh SP (2013) Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leuk Res 37:287\u2013292","journal-title":"Leuk Res"},{"key":"4026_CR7","first-page":"5658","volume":"106","author":"RE Gale","year":"2005","unstructured":"Gale RE, Hills R, Kottaridis PD et al (2005) No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 106:5658\u20135665","journal-title":"Blood."},{"key":"4026_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","volume":"30","author":"S Brunet","year":"2012","unstructured":"Brunet S, Labopin M, Esteve J, Cornelissen J, Soci\u00e9 G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30:735\u2013741","journal-title":"J Clin Oncol"},{"key":"4026_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ajh.24632","volume":"92","author":"S Gaballa","year":"2017","unstructured":"Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO (2017) Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol 92:331\u2013337","journal-title":"Am J Hematol"},{"key":"4026_CR10","doi-asserted-by":"crossref","unstructured":"Huang Q, Chen W, Gaal KK et al A rapid, one step assay for simultaneous detection of FLT3\/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 142:489\u2013492","DOI":"10.1111\/j.1365-2141.2008.07205.x"},{"key":"4026_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453\u2013474","journal-title":"Blood."},{"key":"4026_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/ctr.12495","volume":"29","author":"Y Ma","year":"2015","unstructured":"Ma Y, Wu Y, Shen Z et al (2015) Is allogeneic transplantation really the best treatment for FLT3\/ITD-positive acute myeloid leukemia? A systemic review. Clin Transpl 29:149\u2013160","journal-title":"Clin Transpl"},{"key":"4026_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.bbmt.2011.02.003","volume":"17","author":"AE DeZern","year":"2011","unstructured":"DeZern AE, Sung A, Kim S, Smith BD, Karp JE, Gore SD, Jones RJ, Fuchs E, Luznik L, McDevitt M, Levis M (2011) Role of allogeneic transplantation for FLT3\/ITD acute myeloid leukemia: outcomes from 133 consecutive newly-diagnosed patients from a single institution. Biol Blood Marrow Transplant 17:1404\u20131409","journal-title":"Biol Blood Marrow Transplant"},{"key":"4026_CR14","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","volume":"22","author":"B Oran","year":"2016","unstructured":"Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G (2016) Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant 22:1218\u20131226","journal-title":"Biol Blood Marrow Transplant"},{"key":"4026_CR15","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3324\/haematol.2012.062638","volume":"97","author":"A Nazha","year":"2012","unstructured":"Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F (2012) Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete remission and relapse in patients with acute myeloid leukemia. Haematologica. 97:1242\u20131245","journal-title":"Haematologica."},{"key":"4026_CR16","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.bbmt.2014.08.015","volume":"20","author":"MR Grunwald","year":"2004","unstructured":"Grunwald MR, Tseng LH, Lin MT et al (2004) Improved FLT3\/ITD PCR assay predicts outcome following allogenic transplant for AML. Biol Blood Marrow Transplant 20:1989\u20131995","journal-title":"Biol Blood Marrow Transplant"},{"key":"4026_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00277-018-3265-1","volume":"97","author":"X Zhao","year":"2018","unstructured":"Zhao X, Wang Z, Ruan G, Liu Y, Wang Y, Zhang X, Xu L, Huang X, Chang Y (2018) Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Ann Hematol 97:967\u2013975","journal-title":"Ann Hematol"},{"key":"4026_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, D\u00f6hner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, D\u00f6hner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454\u2013464","journal-title":"N Engl J Med"},{"key":"4026_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2991\/chi.d.190310.001","volume":"1","author":"A Bazarbachi","year":"2019","unstructured":"Bazarbachi A, Labopin M, Battipaglia G et al (2019) Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. A retrospective acute leukemia working party- European Society for Blood and Marrow Transplant Study. Clin Hematol Int 1:58\u201374","journal-title":"Clin Hematol Int"},{"key":"4026_CR20","doi-asserted-by":"crossref","unstructured":"Maziarz RT, Patnaik MM, Scott BL, et al. (2018) Radius: a phase 2 randomized trial investigating standard of care +\/\u2212 midostaurin after allogeneic stem cell transplantation in FLT3\/ITD-mutated AML. 60th ASH Annual Meeting and Exposition, San Diego, CA. Abstract 633","DOI":"10.1182\/blood-2018-99-113582"},{"key":"4026_CR21","doi-asserted-by":"crossref","unstructured":"Burchert A, Bug G, Finke J, et al. (2018) Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicenter Sormain Trial. . 60th ASH Annual Meeting and Exposition, San Diego, CA. Abstract 661","DOI":"10.1182\/blood-2018-99-112614"},{"key":"4026_CR22","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","volume":"20","author":"A Di Stasi","year":"2014","unstructured":"Di Stasi A, Milton DR, Poon LM et al (2014) Similar transplantation outcome for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 20:1975\u20131981","journal-title":"Biol Blood Marrow Transplant"},{"key":"4026_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00432-016-2290-5","volume":"143","author":"M Fleischmann","year":"2017","unstructured":"Fleischmann M, Schnetzke U, Schrenk KG, Schmidt V, Sayer HG, Hilgendorf I, Hochhaus A, Scholl S (2017) Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol 143:337\u2013345","journal-title":"J Cancer Res Clin Oncol"},{"key":"4026_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3324\/haematol.2017.178251","volume":"103","author":"X Poire","year":"2018","unstructured":"Poire X, Labopin M, Polge E et al (2018) Allogeneic stem cell transplantation benefits for patients \u226560 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the acute leukemia working Party of the European Society for blood and marrow transplantation. Haematologica. 103:256\u2013265","journal-title":"Haematologica."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04026-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T05:17:51Z","timestamp":1619327871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04026-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4026"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04026-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"17 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GH has received a speaker honorarium from Novartis. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any animal studies performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}